

INTERIM REPORT

January to March 2010



 **VITA 34**

CONSOLIDATED KEY FIGURES

		01/01- 03/31/2010	01/01- 03/31/2009
STEM CELL PREPARATIONS			
Umbilical cord blood storages	Number	2,477	2,448
PROFIT / LOSS			
Revenues	EUR k	3,491	3,402
Gross profit	EUR k	2,237	2,270
EBIT	EUR k	160	-195
Period result	EUR k	265	-84
		03/31/2010	03/31/2009
BALANCE SHEET / CASH FLOW			
Total assets	EUR k	29,876	29,134
Equity	EUR k	19,010	18,040
Equity ratio	%	63.6	61.9
Liquid funds including other financial assets	EUR k	7,173	5,728
Capital expenditures*	EUR k	216	71
Depreciation*	EUR k	125	130
Cash flow from operating activities	EUR k	-594	-1,501
EMPLOYEES			
Employees (as of March 31)	Number	96	102
Personnel expenditures	EUR k	1,134	1,268

* Information for tangible and intangible assets

CONTENTS

	PAGE
LETTER TO THE SHAREHOLDERS	5
GROUP INTERIM REPORT	6
1 Summary	6
2 Revenue and Profit Situation	6
3 Financial and Asset Situation	7
4 Investments	9
5 Employees	9
6 VITA 34 on the Capital Market	9
7 Risks and Market Opportunities	10
8 Outlook	11
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS	12
1 Condensed Consolidated Statement of Income	12
2 Condensed Consolidated Statement of Comprehensive Income	13
3 Condensed Consolidated Statement of Financial Position	14
4 Condensed Consolidated Statement of Cash Flows	16
5 Condensed Consolidated Statement of Changes in Group Equity	17
NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS	18
FINANCIAL CALENDAR AND CONTACT	21

LETTER TO THE SHAREHOLDERS

Dear Shareholders,

The beginning of the year 2010 was successful for VITA 34, despite the ongoing difficult economic situation. Storage figures, revenues and EBIT were higher than the results of the prior year's period. Altogether, we prepared and cryo-stored 2,477 umbilical cord blood preparations in our glass laboratory in Leipzig in Q1. We can also be satisfied with revenues of EUR 3.5 million.

We are also proud of our earnings before interest and taxes [EBIT], which were EUR 0.2 million in the first quarter. In Q1 of the prior year we had still posted a loss in the amount of EUR 0.2 million. We are confident that we can continue this positive trend relating to our profits for the year as a whole.

We have been able to optimize our marketing and sales strategy for 2010 and enrich it with new realized and planned cooperative efforts. The effects can, however, only be evaluated over a longer period of time of several quarters.

In addition, during this quarter our foreign partners have contributed significantly to the positive development of our company. We now store preparations in Leipzig for customers from Spain, Italy, Austria, Switzerland and Slovenia. Apart from the many years of good cooperation with the Spanish company, Secuvita, as of Q1 2009 our services have also been available to parents in Slovenia. In this EU country with more than 20,000 births annually, we are working together with our local partner Izvorna Celiica d.o.o. As of August 2009 there has also been a cooperation with Italy's Sorgente S.r.l. We have been able to achieve consistent growth with storages from the Italian market (500,000 births per annum).

The VITA 34 "Made in Germany" quality has proven itself in our foreign cooperative efforts. We place emphasis on the highest standards of quality, in logistics as well as in the work in the lab and in cryo-conservation.

The medical justification for the use of umbilical cord blood in the therapy of severe diseases and in regenerative medicine is documented by constantly increasing application figures. The main fields of application for umbilical cord blood in general are brain damage, Type 1 diabetes and leukemia. In the first quarter three children have already been treated with umbilical cord blood stored at VITA 34.


Additional proof of the significance of umbilical cord blood in regenerative medicine is provided by scientific publications, which point out that stem cells from umbilical cord blood are better suited to so-called "reprogramming" to pluripotent stem cells than regular cells or stem cells from other sources.

We are convinced that this advance in medicine will further increase the significance of stem cells from umbilical cord blood. VITA 34 will profit especially from this.

Leipzig, April 15, 2010



Dr. Eberhard Lampeter



Jörg Ulbrich

GROUP INTERIM REPORT

01/01 to 03/31/2010

1 SUMMARY

VITA 34 is by far the largest private umbilical cord blood bank in the German-speaking countries, with more than 70,000 units of umbilical cord blood stored. Moreover, VITA 34 services are offered in various configurations in additional European countries. Thus, in addition to the German-speaking markets Austria and Switzerland, VITA 34 is also represented by cooperation partners in Spain, Slovenia and Italy. In the expansion, VITA 34 benefits from the fact that as the oldest private umbilical cord blood bank in Europe it has a great deal of experience in the entire process chain of the collection, analysis and storage of umbilical cord blood.

The VITA 34 target group consists of expecting parents. They must be informed about the possibility of storage and have the justification for it explained to them, so that they are prepared to use the necessary financial resources for storage. Approaching expecting parents is, therefore, one of the keys to the further development of VITA 34. To date in Germany umbilical cord blood is only privately stored in some 2 percent of births. Other countries have shown that the question of money is not the primary consideration when considering storage. For example, in Greece or in several Asian countries, storages have already reached double-digit percentages in relation to annual births.

Stem cells are expected to play an increasingly greater role in the treatment of diseases and in regenerative medicine in the future. Therefore, the VITA 34 product range will enter increasingly into the public eye. The significance of umbilical cord blood will increase in the area of third-party donations, as well. VITA 34 will profit from this development thanks to a cooperation with the German Umbilical Cord Blood Bank (NKR North-German Bone Marrow and Stem Cell Donation Registry).

In addition, VITA 34 is opening up potential revenues with product differentiation. For example, with regard to the scope of the offer, but also with regard to payment methods, solutions are being offered tailored to different customer groups. The VITA 34 max product deserves special mention. Here, additional tests and preventative screenings are performed on the collected umbilical cord blood, for example, to detect a genetic predisposition for various diseases.

2 REVENUE AND PROFIT SITUATION

In Q1 2010 2,477 stem cell preparations were stored at VITA 34. Thus, they were slightly above the level of the previous year, when 2,448 umbilical cord blood storages were achieved. Business with the cooperation partners continued to grow, including Secuvita S.L., Izvorna Celica d.o.o., Sorgente S.r.L. and Deutsche Nabelschnurblutbank (NKR) [German Umbilical Cord Blood Bank].

VITA 34 books revenues some one to two months after the storage of a transplant. Storages, therefore, precede the development of revenues. In Q1 VITA 2010 earned revenues totaling EUR 3.5 million, thus attaining the level of the prior year's quarter, in which EUR 3.4 million in revenues were also generated.



Gross profit in Q1 2010 was EUR 2.2 million and, therefore, was only slightly below the value of Q1 2009, when EUR 2.3 million were generated.

The marketing and sales expenses of EUR 1.7 million were significantly less in Q1 2010 than the EUR 2.1 million posted in Q1 of the prior year. The optimization in sales led to a noticeable increase in efficiency and a reduction in expenses. Administrative expenses in Q1 2010 were EUR 0.6 million and were, therefore, at the level of the prior year's quarter.

Earnings before interest and taxes [EBIT] improved markedly in Q1 2010 as compared to the prior years quarter from EUR -0.2 million to EUR 0.2 million. As compared with the prior year's period the financial result increased from EUR -9,000 to EUR 55,000 in Q1 2010.

The income tax credit in Q1 2010 was EUR 50,000 following EUR 120,000 in the prior year's quarter.

After a loss of EUR -0.1 million in Q1 2009, the period profit in Q1 2010 improved to EUR 0.3 million.

3 FINANCIAL AND ASSET SITUATION

Financial Situation

The liquid funds of EUR 7.2 million were higher in Q1 2010 than the figure for the prior year, when EUR 4.7 million were posted as of March 31. As compared with year's end 2009 with EUR 8.1 million, however, liquid funds were lower. The reduction of liquidity is attributed significantly to the decrease in liabilities at the amount of EUR 0.9 million.

The cash flow from operating activities in Q1 2010 was EUR -0.6 million, following EUR -1.5 million in the prior year's period.

This improvement results mainly from the reduction in trade receivables and the significantly higher earnings before taxes in the first three months of the current fiscal year in comparison to Q1 2009.

The cash flow from investing activities was EUR -0.3 million after three months. This was primarily the result of the acquisition of intangible assets of EUR 0.2 million. On the level of the cash flow from financing activities there were no activities both in Q1 2010, as well as in Q1 2009.

Assets

Unchanged, VITA 34 International AG has a solid balance sheet structure. The equity ratio as compared with year's end 2009 improved slightly and was at a high level at the end of Q1 with 63.6 percent. The balance sheet total as of March 31, 2010 was EUR 29.9 million, and decreased as compared with the total of EUR 31.2 million at the end of 2009.

The largest item on the asset side was the goodwill of VITA 34 AG, which was posted unchanged on the balance sheet of VITA 34 International AG at EUR 11.9 million. In all, the non-current assets amounted to EUR 19.2 million. Plant and equipment of EUR 3.3 million were nearly unchanged as compared to the value of the prior year's quarter.


Increasing number of donated preparations for the German Umbilical Cord Blood Bank stored

The current assets and liquid funds were in total EUR 10.7 million, where cash and cash equivalents of EUR 5.2 million represented the largest item. Cash and cash equivalents of EUR 6.1 had been posted at the end of 2009. Receivables decreased to EUR 1.9 million at the end of the reporting period, following EUR 2.3 million at year's end 2009.

The largest item on the liabilities side at the end of Q1 was equity of EUR 19.0 million. The growth as compared with the 2009 year end figure was mainly the result from the period result earned in 2010. The issued capital remained unchanged at EUR 2.6 million.

The non-current liabilities and deferred income at the end of Q1 2010 totaled EUR 8.8 million, the same figure as that at the end of 2009. Deferred income increased only slightly from EUR 5.6 million to EUR 5.7 million. This item contains storage fees pre-paid by customers, which are dissolved and booked as income over the course of the storage term.

The current liabilities and deferred income of EUR 2.1 million at the end of the reporting period were significantly under the 2009 year end value of EUR 3.5 million. This was mainly due to the significantly lower other liabilities, which were only EUR 0.4 million as of March 31, 2010, following EUR 1.3 million at the end of 2009.





4 INVESTMENTS

VITA 34 made investments in plant and material and intangible assets in the amount of EUR 0.2 million in Q1 2010. In comparison with the prior year's period, in which investments amounted to EUR 0.1 million, more was invested in the first three months of 2010. The investments in the reported period were mainly in pre-payments for process software in the IT department, new acquisitions in the laboratory and in expanding the cryo and storage capacities at the company's headquarters in Leipzig. It is expected that there will be no significant change in the investment level in the coming quarter.

5 EMPLOYEES

As of March 31, 2010 VITA 34 employed 96 people in the group (without trainees and temporary workers). As a result of a headcount adjustment, this meant a reduction of the number of employees by 5 as compared to year's end 2009.

At the end of Q1 there were 42 employees in production and quality assurance, in marketing and sales 34 and in the commercial department 20 employees. A member of the management board as well as the business development department is counted among the commercial department.


6 VITA 34 ON THE CAPITAL MARKET

After the slight recovery of the German stock market in 2009, the German stock index DAX increased by approximately 3.3 percent from December 30, 2009 to March 31, 2010. The SDAX, an indicator for German second-line stocks, has improved by approximately 9.8 percent.

The VITA shares were able to improve significantly in the first three months of 2010, with a share price increase of some 15 percent. The price per share increased from EUR 4.55 on December 30, 2009 to EUR 5.10 on March 31, 2010 in the Xetra electronic trading system. The share reached its Q1 high of EUR 5.55 in Q1 on February 22. The low of EUR 4.40 was noted at the beginning of the quarter, on January 20.

In the first three months of 2010, the average volume of shares traded increased by nearly 42 percent as compared to the volume achieved in 2009. Per day 4,112 shares were traded on average on all German exchanges. Of these, a majority of 3,212 were on Xetra, which represented the most liquid exchange. As Designated Sponsor for VITA 34, ICF Kursmakler AG ensures tight margins between bid and offer prices, thus increasing the attractiveness of the share for investors.

There were no changes in the fundamental shareholder structure: The percentage of VITA shares held by founders and management is now 15.1 percent. The largest single shareholder since the IPO has been the American health insurance company Independence Blue Cross with a share of 20.7 percent. Landesbank Baden-Württemberg held 15.8 percent via its subsidiaries CFH Beteiligungsgesellschaft mbH (9.15%) and SBF Sächsische Beteiligungsfonds GmbH (6.68%) of VITA 34 International AG. Free-float according to the Deutsche Börse AG definition was 48.4 percent.



After the publication of the 2009 Annual Report on February 25, 2010, the company experienced very positive feedback from the capital market thanks to the detailed, transparent and very quick communication. We will continue to maintain this level.

VITA 34 will participate in the Munich Capital Market conference in April. In addition, VITA 34 will present as usual at important capital market conferences such as the German Equity Forum in November 2010.

In-depth information of the development of business and on the VITA 34 share can be found on the company's home page www.vita34.com, in the Investor Relations Section.

Investors and interested parties can download the 2009 Annual Report from the Investor Relations section of the company's website.

In addition, VITA 34 is available for investor questions via E-mail at ir@vita34.com.

7 RISKS AND MARKET OPPORTUNITIES

With regard to risks and market opportunities, there have been no significant changes to the risks and opportunities listed in the 2009 Annual Report at VITA 34 in Q1 2010.

INFORMATION AND KEY FIGURES ON THE SHARES

Ticker symbol / Reuters symbol	V3V / V3VGn.DE
Securities number / ISIN	A0BL84 / DE000A0BL849
Initial quotation	03/27/2007
Market segment	Prime Standard
Index	CDAX, Prime All Share, Technology All Share, Prime IG Biotechnology
Opening / High / Low / Closing price Q1 2010 (Xetra)	4.55 EUR / 5.55 EUR / 4.40 EUR / 5.10 EUR
Number of shares issued	2,646,500
Freefloat as of 03/31/2010	48.4 %
Market capitalization as of 03/31/2010	13.5 Mio. EUR
Designated Sponsor	ICF Kursmakler AG

At VITA 34 stored umbilical cord blood was applied three times in 2010.

8 OUTLOOK

With regard to the economic situation and the reticence for consumption on the part of German households, VITA 34 is not striving for revenue increases in the core business at any price for the current fiscal year. Instead, all sensible measures will be taken to set the course for growth beyond the year 2010. In the next several months VITA 34 will continue to concentrate on the consolidation and increase in effectiveness of business activities and internal processes. A significantly positive EBIT is the target for the end of the year 2010.

To this end, the German market for the storage of umbilical cord blood will continue to be developed by both optimizing activities in the area of advertising, as well as approaching experts and multipliers using the field force, and through new cooperative efforts, some of which have already been implemented. Here, VITA 34 has the expansion of the value chain in focus. Apart from potential synergies for the core business, additional fields of business are to be opened up.

The expert storage of stem cell transplants for the German Umbilical Cord Blood Bank (NKR North German Bone Marrow and Stem Cell Donation Register) will contribute to an important component of positioning of the company as a complete provider, and to an increased and solidified reputation amongst multipliers.

In 2010 VITA 34 will significantly expand the number of preparations listed in the public register and, thus, make a contribution to the provision of donor preparations.


In the coming quarters, VITA 34 also expects an increasing contribution to revenues and storages to come from the cooperation partners Sorgente S.r.l. in Italy and Izvorna Celica d.o.o. in Slovenia.

With nearly 70,000 umbilical cord blood storages and many years of experience as a complete provider, VITA 34 considers itself to be well equipped for the continuous expansion of business activities.

Leipzig, April 15, 2010
Management Board of VITA 34 International AG



Dr. Eberhard Lampeter



Jörg Ulbrich

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

03/31/2010

1 CONDENSED CONSOLIDATED STATEMENT OF INCOME

EUR K	NOTE	01/01/- 03/31/2010	01/01/- 03/31/2009
Continuing operations			
Revenue		3,491	3,402
Cost of sales		-1,254	-1,132
Gross profit on sales		2,237	2,270
Other operating income		237	261
Selling expenses		-1,658	-2,118
Administrative expenses		-548	-553
Other operating expenses		-108	-55
Net operating profit/loss		160	-195
Finance revenue		91	43
Finance costs		-36	-52
Earnings before taxes		215	-204
Income tax income	5	50	120
Period result		265	-84
Earnings per share, basic / diluted (EUR)			
		0.10	-0.03

2 CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

EUR K	NOTE	01/01/ 03/31/2010	01/01/ 03/31/2009
Period result		265	-84
Changes recognized in other comprehensive income		-3	0
Changes recognized in profit or loss		4	0
Difference from currency translation		1	0
Changes recognized in other comprehensive income		-19	0
Changes recognized in profit or loss		-110	0
Gains/losses on available-for-sale financial assets		-129	0
Total comprehensive income for the year after tax		137	-84

3 CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (ASSETS)

EUR K	NOTE	03/31/2010	12/31/2009
Non-current assets			
Goodwill		11,911	11,911
Intangible assets		916	795
Property, plant and equipment		3,289	3,319
Investments		0	155
Other financial assets		35	35
Deferred tax assets		522	667
Non-current trade receivables		1,797	1,805
Restricted Cash		695	695
		19,165	19,382
Current assets			
Inventories		502	554
Trade receivables		1,923	2,334
Other receivables and assets		1,113	825
Short-term investments		2,000	2,000
Cash and cash equivalents	4	5,173	6,055
		10,711	11,768
		29,876	31,150

3 CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (EQUITY AND LIABILITIES)

EUR K	NOTE	03/31/2010	12/31/2009
Equity			
Issued capital		2,647	2,647
Capital reserves		23,236	23,236
Revenue reserves		-6,873	-7,138
Other reserves		0	128
		19,010	18,873
Non-current liabilities and deferred income			
Interest-bearing loans		1,375	1,375
Silent partners' interests		940	940
Deferred grants		832	846
Deferred income		5,656	5,616
		8,803	8,777
Current liabilities and deferred income			
Trade payables		508	813
Provisions		361	363
Income tax liabilities		0	195
Interest-bearing loans		125	125
Deferred grants		50	50
Other liabilities		368	1,314
Deferred income		651	640
		2,063	3,500
		29,876	31,150

4 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EUR K	NOTE	01/01/ 03/31/2010	01/01/ 03/31/2009
Cash flow from operating activities			
Earnings before taxes		215	-204
Adjusted for:			
Amortization and depreciation		125	130
Profit / loss from disposal of non-current assets		0	5
Other non-cash expenses and income		132	97
Exchange differences		-6	-7
Finance revenues		-91	-43
Finance expenses		36	52
Expenses of share-based compensation		0	19
Cash flow from ordinary operations:			
+/- Trade receivables and other receivables and assets		120	-311
+/- Inventories		52	22
+/- Trade payables and other liabilities		-1,251	-1,162
+/- Provisions		-2	-103
+/- Deferred income		51	53
Interest paid		25	-46
Income taxes paid		0	-3
Cash flow from operating activities		-594	-1,501
Cash flow from investing activities			
Purchase of intangible assets		-179	-25
Purchase of property, plant and equipment		-37	-46
Purchase of short-term financial asset		0	-1,000
Interest received		-36	22
Cash flow from investing activities		-252	-1,049
Cash flow from financing activities			
Changes in silent partnerships		0	0
Changes in loans		0	0
Cash flow from financing activities		0	0
Net change in cash and cash equivalents		-846	-2,550
Cash and cash equivalents at the beginning of the reporting period		6,055	6,374
Change in cash and cash equivalents from changes in the consolidation scope		-38	0
Net foreign exchange difference		2	7
Cash and cash equivalents at the end of the reporting period	4	5,173	3,831
Short-term investments		2,000	897
Liquid funds		7,173	4,728

5 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN GROUP EQUITY

EUR K	ISSUED CAPITAL	CAPITAL RESERVES	REVENUE RESERVES	OTHER COMPREHENSIVE INCOME		TOTAL EQUITY
				TRANSLATION RESERVE	AVAILABLE- FOR-SALES ASSETS	
Balance as of January 1, 2009	2,647	23,192	-7,734	0	0	18,105
Share-based compensation		19				19
Period result			-84			-84
Comprehensive income	0	19	-84	0	0	-65
Balance as of March 31, 2009	2,647	23,211	-7,818	0	0	18,040
Balance as of January 1, 2010	2,647	23,236	-7,138	-1	129	18,873
Available-for-sale shares					-129	-129
Difference arising from foreign currency translation				1		1
Period result			265			265
Comprehensive income	0	0	265	1	-129	137
Balance as of March 31, 2010	2,647	23,236	6,873	0	0	19,010

NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1 COMPANY INFORMATION

The parent VITA 34 International AG (the "Company") domiciled in Leipzig (Germany), at Deutscher Platz 5a, and filed in the register court of the Leipzig district court under HRB 20339 is a pure holding company and carries out management and financing functions for its subsidiaries. Its subsidiaries (together with the Company referred to as the "Group") operate in the field of cord blood storage. Their business purpose is to collect, process and store stem cells from cord blood and to develop cell therapeutics.

The unaudited, condensed, consolidated interim financial statements for the period from January 1 until March 31, 2010 were approved for publication by the Management Board on April 15, 2010.

2 CONSOLIDATION SCOPE

The consolidated interim financial statements incorporate the financial statements of VITA 34 International AG and Vita 34 AG, Leipzig, Germany. The financial statements of CorCell Inc., Philadelphia, PA, USA, were no longer included in the consolidated financial statements of the company due to their diminished significance.

The following effects resulted in the profit situation of the group as of March 31, 2010 by not incorporating CorCell in the consolidation scope of the company.

EFFECTS FROM DECONOSOLIDATION OF CORCELL INC.	2010
	EUR K
Investments	-138
Other current assets	-11
Cash and cash equivalents	-38
Other liabilities	121
Expenses arising from foreign currency translation	-4
Income from the reversal of provisions for available-for-sale assets	110
Income from deconsolidation	40

Since CorCell Inc. no longer conducts its own business activities, the investment is listed in the consolidated interim financial statements at EUR 1.00 under the non-current other financial assets.

The profit of EUR 40k from the de-recognition of the assets and liabilities is listed in the condensed consolidated statement of income under other operating income.

3 ACCOUNTING AND VALUATION PRINCIPLES

3.1 Basis for the Preparation of the Financial Statements

The preparation of the consolidated interim financial statements for the period from January 1 until March 31, 2010 has been conducted in accordance with IAS 34 "Interim Financial Reporting".

The condensed consolidated interim financial statements do not contain all of the explanations and information prescribed for the annual financial statements and should be read in conjunction with the consolidated financial statements as of December 31, 2009.

3.2 Significant Accounting and Valuation Methods

The accounting and valuation methods used to prepare the condensed consolidated interim financial statements correspond with the methods used in the preparation of the consolidated financial statements for the fiscal year as of December 31, 2009.

The group used the following new and revised IFRS standards and interpretations for the first time as of January 1, 2010:

- :: Amendments to IFRS 1: First-time Adoption of International Financial Reporting Standards
- :: Amendments to IFRS 2: Share-based Payment
- :: Amendments to IFRS 3: Business Combinations
- :: Amendments to IAS 27: Consolidated and Separate Financial Statements
- :: Amendments to IAS 39: Financial Instruments: Recognition and Measurement – Eligible Hedged Items
- :: IFRIC 12: Service Concession Arrangements
- :: IFRIC 15: Agreements for the Construction of Real Estate
- :: IFRIC 16: Hedges of a Net Investment in a Foreign Operation
- :: IFRIC 17: Distributions of Non-cash Assets to Owners
- :: IFRIC 18: Transfers of Assets from Customers
- :: Improvements to IFRS in 2008
- :: Improvements to IFRS in 2009

The standards and interpretations required to be used for the first time starting January 1, 2010 resulted in no significant effects on the interim financial statements of VITA 34 International AG.

4 CASH AND CASH EQUIVALENTS

For the purposes of the consolidated statement of cash flows, the cash and cash equivalents consist of the following:

CASH AND CASH EQUIVALENTS	03/31/2010	03/31/2009
	EUR K	EUR K
Cash at banks and in hand	5,173	3,831

5 INCOME TAXES

Treatment of tax losses carried forward and deferred tax claims

Within the context of a tax audit conducted at VITA 34 AG, which reached back to tax year 2002, the financial authorities arrived at a different opinion than VITA 34 AG with regard to the tax treatment of deferred income from storage fees paid in advance.

This resulted in an assessment that modified the VITA 34 AG tax return, the result of which led to a reduction in the tax loss carried forward as of the relevant date December 31, 2002. VITA 34 AG initiated legal action against this assessment. In March 2010 the case was won and the tax treatment by VITA 34 AG of deferred income from storage fees paid in advance was determined to be justified. Income from the reversal of a provision for business tax in the amount of EUR 195k resulted from winning this case.

The adjustment of valuation differences from deferred income between the tax balance sheet and the consolidated interim financial statements, as well as the adjustment of the tax loss carried forward result of winning the case led altogether to a reduction in the deferred taxes and, therefore, to additional expenditures in the amount of EUR 145k.

The major components of the income tax income listed in the condensed consolidated statement of income consist of the following:

MAJOR COMPONENTS OF THE INCOME TAX INCOME / EXPENSE	01/01-03/31/2010	01/01-03/31/2009
CONSOLIDATED STATEMENT OF INCOME	EUR K	EUR K
Current income tax		
Current income tax income/expense	-195	3
Deferred income tax		
Origination and reversal of temporary differences	266	-7
On unused tax losses	-121	-116
Income tax income	-50	-120

6 SEGMENT REPORTING

The Company only has one reportable segment because the Group's operations only concern the storage of umbilical cord blood.

6.1 Information on geographical segments

The Company generates income exclusively in Europe. In the period from January 1 to March 31, 2010 the geographical segment comprising Germany, Austria and

Switzerland generated income of EUR 2,927k (January 1 to March 31, 2009: EUR 2,872k) while the Spanish segment recorded a figure of EUR 564k (January 1 to March 31, 2009: EUR 530k).

Income is allocated to geographical segments based on the revenue generated in the individual countries.

6.2 Information on important customers

Only one external customer accounts for more than 10 percent of the Group's total income. It is disclosed under total income for the Group and totaled EUR 564k for the period from January 1 to March 31, 2010 (January 1 to March 31, 2009: EUR 530k).

7 RELATED PARTY DISCLOSURES

The following table provides the total amount of transactions which have been entered into with related parties for the period from January 1 to March 31, 2010 and 2009:

EXPENSES TO RELATED PARTIES	TOTAL AMOUNT OF TRANSACTIONS	
PERIOD FROM 01/01 – 03/31/	2010	2009
	EUR K	EUR K
Compensation of key management personnel of the Group:		
Short-term benefits:		
- Remuneration of the Supervisory Board	7	15
- Management Board salaries	97	197
Share-based compensation		
- The Managements Board of VITA 34 AG	0	19

FINANCIAL CALENDAR 2010

February 25, 2010	Publication of Annual Report
April 15, 2010	Publication of Q1 Report
July 13, 2010	Publication of Q2 Report
July 13, 2010	Annual General Meeting
October 14, 2010	Publication of Q3 Report
November 2010	German Equity Forum

CONTACT

Dr. med. Eberhard F. Lampeter
VITA 34 International AG
Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-40
Fax: +49 341 48792-39
E-mail: ir@vita34.com

Press:

Axel Mühlhaus/Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
60318 Frankfurt

Telephone: +49 69 905505-52
Fax: +49 69 905505-77
E-mail: vita34@edicto.de

This Interim Report was published in German and English on April 15, 2010 and is available for download on our internet site.

VITA 34 on the Internet: www.vita34.com

VITA 34 International AG

Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-40
Fax: +49 341 48792-39

Internet: www.vita34.com
E-mail: ir@vita34.com

